Patent ID: 8604020

Claim:
A pharmaceutical composition comprising a molecular crystal form of (R)-(+)-7-(3-amino-2,3,4,5,6,7-hexahydro-1H-1-azepin-1-yl)-1cyclopropyl-8-chloro-6-fluoro-1,4-dihydro-4-oxoquinoline-3-carboxylic acid characterized by an X-ray powder diffraction (“XRPD”) spectrum that comprises peaks at 2θ angles of 10.6, 15, 19.7, 21.1, and 22°±0.2°; a DSC melting peak at 288° C.; and a 13 C NMR spectrum having peaks at 23.3, 27.7, 41.1, 54.5, 116.6, and 153.5 ppm; wherein the pharmaceutical composition is a suspension comprising particles of said molecular crystal form.